Results 61 to 70 of about 1,228 (155)

In vitro susceptibility of nonfermenting Gram-negative rods tomeropenem–vaborbactam and delafloxacin Suppl. Table 1

, 2023
Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with
Thomas Guillard (12633958), Amelie Bosphore (14549900), Antoine Roux (14549894), Eric Farfour (11021923), Corentine Alauzet (14549885), Lise Cremet (14549888), Louise Ruffier d’Epenoux (14549879), Sophie Moussalih (14549891), Marc Vasse (335648), Sylvie C de Verdiere (14549897), Stephane Corvec (14549903), Anaelle Muggeo (14549882)   +11 more
core   +1 more source

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

Pharmaceuticals, 2023
Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections.
Davide Carcione, Jari Intra, Lilia Andriani, Floriana Campanile, Floriana Gona, Silvia Carletti, Nicasio Mancini, Gioconda Brigante, Dario Cattaneo, Sara Baldelli, Mattia Chisari, Alessandra Piccirilli, Stefano Di Bella, Luigi Principe   +13 more
doaj   +1 more source

Lack of phototoxicity potential with delafloxacin in healthy male and female subjects:comparison to lomefloxacin [PDF]

, 2018
Aims: Delafloxacin is a fluoroquinolone antibiotic recently approved by the FDA for treatment of acute bacterial skin and skin structure infections (ABSSSI).
Cammarata, S., J. Ferguson, Ferguson, J., S. Ibbotson, Lawrence, L., Ibbotson, S., E. Duffy, Paulson, S., R. S. Dawe, S. Cammarata, L. Lawrence, S. Paulson, Duffy, E., Dawe, R. S.   +13 more
core   +1 more source

Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?

Pharmaceutics, 2023
Antibacterial fluoroquinolones (FQs) are frequently used in treating infections. However, the value of FQs is debatable due to their association with severe adverse effects (AEs).
Aura Rusu, Alexandra-Cristina Munteanu, Eliza-Mihaela Arbănași, Valentina Uivarosi   +3 more
doaj   +1 more source

A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia

Expert Review of Clinical Pharmacology, 2022
Community-acquired bacterial pneumonia (CABP) is the most common infectious cause of hospital admission in adults, and poses a significant clinical and economic burden. At the same time, antimicrobial resistance is increasing worldwide with only a few new antibiotics developed in recent years.
Silvia Gómez-Zorrilla, Elena Sendra, Juan P. Horcajada   +2 more
openaire   +5 more sources

In vitro susceptibility of nonfermenting Gram-negative rods to meropenem–vaborbactam and delafloxacin

, 2023
International audienceAim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. ( Achr), Burkholderia cepacia complex ( Bcc) and Stenotrophomonas maltophilia ( Smal).
Moussalih, Sophie, Alauzet, Corentine, Crémet, Lise, Guillard, Thomas, de Verdière, Sylvie, Farfour, Eric, D’epenoux, Louise Ruffier, Corvec, Stéphane, Vasse, Marc, Muggeo, Anaëlle, Bosphore, Amélie, Roux, Antoine   +11 more
core   +1 more source

High-level delafloxacin resistance through the combination of two different mechanisms in Staphylococcus aureus

, 2023
Delafloxacin is a new fluoroquinolone indicated for the treatment of complicated bacterial skin infections caused by Staphylococcus aureus. Despite its recent approval by the US Food and Drug Administration, the emergence of S.
Aznar Fernández, María, Cisneros, José Miguel, Lepe, José A., José Manuel Ortiz de la Rosa, Carlos S Casimiro-Soriguer, Rodríguez-Villodres, Ángel, Ortiz de la Rosa, José Manuel, Casimiro-Soriguer, Carlos S., María Aznar Fernández, José Antonio Lepe, Ángel Rodríguez-Villodres, José Miguel Cisneros   +11 more
core   +1 more source

Antibiotic‐mediated immune modulation in periodontitis

Periodontology 2000, EarlyView.
Abstract Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth. Although initiated by dysbiotic microbial communities, its progression is largely driven by the host's uncontrolled inflammatory response. While antibiotics have conventionally been employed in periodontitis therapy for their antimicrobial ...
Lina J. Suárez, R. M. Arce, Camila Pinheiro Furquim, Cristiane Gonçalves, Alpdogan Kantarci, Magda Feres, Nidia C. Castro dos Santos   +6 more
wiley   +1 more source

2‐Chloro‐5‐(trifluoromethyl)aniline‐Derived Schiff Base Palladium(II) Complexes: From Molecular Design to Acute Toxicity Assessment

ChemistryOpen, Volume 15, Issue 10, October 2026.
Four new Schiff bases derived from 2‐chloro‐5‐(trifluoromethyl)aniline and their corresponding palladium(II) complexes were obtained and analyzed by multiple spectroscopic techniques. Single‐crystal X‐ray diffraction elucidated the structures of all the ligands and complexes 2 and 4. Their toxicity was assessed on Triticum aestivum L.
Andreea Elena Ştefan, Cristina Elena Dinu‐Pîrvu, Sergiu Shova, Ştefania Felicia Bărbuceanu, Teodora Venera Apostol, Diana Carolina Ilieş, Mihaela Badea, Mihaela Dinu, Robert Viorel Ancuceanu, Doina Drăgănescu, Elena Pahonţu   +10 more
wiley   +1 more source

In vitro Aktivität von Delafloxacin und Fosfomycin gegen klinische Methicillin-sensible Staphylococcus aureus und Methicillin-resistente Staphylococcus aureus Isolate

, 2022
Als erfolgreiches menschliches Pathogen ist Staphylococcus aureus häufig verantwortlich für im Krankenhaus erworbene Infektionen. Dabei reichen diese Infektionen von leichten Verläufen bis hin zu lebensbedrohlichen Zuständen.
Berlakovits, Dana
core   +3 more sources